Mitsubishi Tanabe Sees $5 Billion In Sales For MS Drug Gilenya
This article was originally published in PharmAsia News
Executive Summary
Japan's Mitsubishi Tanaba Pharma, with its Gilenya (fingolimod) drug for treating multiple sclerosis, is expected to reach $5 billion in annual sales, making it the drug maker's bestseller